MetaVia’s (MTVA) “Buy” Rating Reiterated at HC Wainwright

MetaVia (NASDAQ:MTVAGet Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $12.00 target price on the stock.

MetaVia Stock Down 2.5 %

MTVA opened at $1.55 on Friday. The firm has a fifty day simple moving average of $1.71. MetaVia has a 12-month low of $1.29 and a 12-month high of $5.30.

MetaVia Company Profile

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Read More

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.